Angela M. Reiersen

TL;DR: In this preliminary study of adult outpatients with symptomatic COVID-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days, and determination of clinical efficacy would require larger randomized trials with more definitive outcome measures.

TL;DR: The Social Responsiveness Scale (SRS) scores for DSM-IV predominantly inattentive subtype and combined subtype ADHD groups were significantly higher than for subjects without DSMIV ADHD (p <.001, both comparisons as discussed by the authors ).

TL;DR: The TOGETHER trial as discussed by the authors evaluated the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to CoV-19.

TL;DR: The Diagnostic and Statistical Manual of Mental Disorders (4th Edition) prohibits the co-diagnosis of attention-deficit/hyperactivity disorder (ADHD) and an autism spectrum disorder (ASD), but recent studies indicate that co-occurrence of clinically significant ADHD and autistic symptoms is common, and some genes may influence both disorders.

TL;DR: The results suggest that in young adults, a substantial proportion of the genetic influences on self-reported autistic and ADHD symptoms may be shared between the two disorders.